PlainPharmaWatch

CMS Open Payments · Tool

Ferring Pharmaceuticals AS vs Merck Healthcare KGaA

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Merck Healthcare KGaA has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,648, versus 1,474 for the other company. Its single largest recorded recipient represents 27.5% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Ferring Pharmaceuticals AS
HHI 1,474 · top recipient 31.9%
Ranked #876 of 1,838 companies by HHI
Merck Healthcare KGaA
HHI 1,648 · top recipient 27.5%
Ranked #827 of 1,838 companies by HHI

Payment Overview

Total Payments
$1.8M
% of Industry
0.0%
Transactions
361
Avg per Transaction
$5.1K
Recipients
83
Avg per Recipient
$22.2K
Payment Types
3
Top Payment Type
Consulting Fee
Total Payments
$1.8M
% of Industry
0.0%
Transactions
459
Avg per Transaction
$3.9K
Recipients
36
Avg per Recipient
$50.3K
Payment Types
4
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Ferring Pharmaceuticals AS vs Merck Healthcare KGaA - total reported payments in CMS Open Payments PY2024

Ferring Pharmaceuticals AS$1.8MMerck Healthcare KGaA$1.8M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Ferring Pharmaceuticals AS

Consulting Fee $48.3K

67.6%

Travel and Lodging $19.1K

26.7%

Food and Beverage $4.1K

5.8%

Merck Healthcare KGaA

Compensation for Services Other Than Consulting $30.3K

35.5%

Travel and Lodging $27.6K

32.3%

Consulting Fee $27.0K

31.6%

Food and Beverage $518.79

0.6%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Ferring Pharmaceuticals AS

  1. 1

    EVE FEINBERG

    $22,829.79 · 2 txns

  2. 2

    FADY SHARARA

    $11,988.48 · 3 txns

  3. 3

    SAHIL KHANNA

    $4,900.00 · 3 txns

  4. 4

    DANIEL DUMESIC

    $4,860.00 · 1 txns

  5. 5

    FLORIAN RIEDER

    $2,472.00 · 1 txns

Merck Healthcare KGaA

  1. 1

    KURT BARNHART

    $23,441.09 · 4 txns

  2. 2

    LEORAH A FREEMAN

    $16,313.79 · 5 txns

  3. 3

    DONALD NEGROSKI

    $15,145.38 · 5 txns

  4. 4

    AHMED Z OBEIDAT

    $6,950.00 · 1 txns

  5. 5

    BARBARA ANN BURTNESS

    $6,583.45 · 6 txns

Summary Comparison

Metric Ferring Pharmaceuticals AS Merck Healthcare KGaA
Total Payments $1.8M $1.8M
% of Industry Total 0.0% 0.0%
Transaction Count 361 459
Avg per Transaction $5.1K $3.9K
Recipient Count 83 36
Avg per Recipient $22.2K $50.3K
Payment Type Count 3 4
Top Payment Type Consulting Fee Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.